Loading clinical trials...
Loading clinical trials...
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
DKN-01 300 mg
DKN-01 600 mg
+1 more
Locations
3
United States
Emory University Hospital
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
May 1, 2013
Primary Completion Date
July 1, 2015
Completion Date
July 1, 2015
Last Updated
August 3, 2025
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Leap Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions